Herantis Pharma Plc · OMXHEX:HRTIS

Herantis Pharma — Investor Presentation (September 2026)

22 slides from Herantis Pharma's investor presentation, September 2026

1. Slide 1: HER-096: Advancing Toward the First Disease-Modifying Treatment for Parkinson's Disease

   HER-096: Advancing Toward the First Disease-Modifying Treatment for Parkinson’s Disease Antti Vuolanto, D.Sc. antti.vuolanto@herantis.com 1

2. Slide 2: Forward-looking statements

   Forward-looking statements © 2014-2026 HERANTIS PHARMA Plc. All rights reserved. 2

3. Slide 3: Herantis Pharma

   Herantis Pharma Nasdaq First North HRTIS Clinical-stage Company Developing Disease-Modifying Therapies for Parkinson’s Disease (PD) Parkinson’s remains a major unmet clinical need • Current treatments improve symptoms but do not slow disease progression • No disease-modifying treatments available HE

4. Slide 4: Executive Team with Deep Expertise in Drug Development

   Executive Team with Deep Expertise in Drug Development Complementary expertise spanning clinical development, translational science, drug discovery, partnering, corporate strategy, and finance Dr Antti Vuolanto, DSc (Tech) Dr Juha Savola, MD, PhD Dr Henri Huttunen, PhD Tone Kvåle Chief Executinve Of

5. Slide 5: HER-096: a strong foundation for Phase 2 development

   HER-096: a strong foundation for Phase 2 development Validated Biology to Phase 2 Earlier Reduced validation of the biology development HER-096 retains key CDNF biology • CDNF biology supporting neuronal MoA confirmation (biomarkers) • Brain-penetrant peptide for survival & function subcutaneous adm

6. Slide 6: Parkinson's Disease: Opportunity Continues to Expand

   Parkinson’s Disease: Opportunity Continues to Expand Unmet clinical need Market is growing rapidly Current therapies only treat the symptoms, not the disease itself 10 è 25 million patients Estimated increase until 2050 Many patients have no symptomatic $ >250 billion benefit or may have significant

7. Slide 7: CDNF Demonstrated Restorative Potential in Parkinson's Disease

   CDNF Demonstrated Restorative Potential in Parkinson’s Disease Neurorestorative Effect of CDNF in Aged Rhesus Monkey PD Model Preliminary Evidence of Biological Response in PD Patients TH staining § Phase 1 study with intraputamenal CDNF in moderately advanced Neurorestoration in the nigrostriatal p

8. Slide 8: HER-096 Mimics CDNF's Neuroprotective Activity via Interaction with GRP78

   HER-096 Mimics CDNF’s Neuroprotective Activity via Interaction with GRP78 GRP78 Serves as the Master Regulator of the Unfolded Protein Response (UPR) Pathway CDNF modulates the UPR to restore ER homeostasis HER-096 is derived from the CDNF / GRP78 binding interface Pathological ER stress CDNF GRP78

9. Slide 9: Parkinson's disease: A Vicious Cycle Drives the Disease Pathology

   Parkinson’s disease: A Vicious Cycle Drives the Disease Pathology Accumulation of Toxic α-Synuclein Aggregates, Chronic ER Stress and Neuroinflammation Parkinson’s disease is driven by proteostasis failure, where impaired protein quality control leads to toxic α-synuclein aggregation that progressiv

10. Slide 10: Preclinical Studies: HER-096 Modulation of UPR Showed Broad Effects on Neuronal Functionality

    Preclinical Studies: HER-096 Modulation of UPR Showed Broad Effects on Neuronal Functionality Restorative Effects on Neuronal Proteostasis and Mitochondrial Function Preclinical studies have shown that in addition to the proteostasis effects, HER-096 has effects that support + g re s gg ER n io s at

11. Slide 11: HER-096 Demonstrates Broad Neurorestorative Effects in a PD Mouse Model

    HER-096 Demonstrates Broad Neurorestorative Effects in a PD Mouse Model Reduced PD pathology is accompanied by preservation of the dopamine system and improved motor function Disease Pathology Dopamine System Functional Outcome -64% Aged α-syn/CBE PD mouse model; HER-096 * p<0.05 10 mg/kg (human-equ

12. Slide 12: HER-096 Restores Motor Function in a Parkinson's Disease Mouse Model

    HER-096 Restores Motor Function in a Parkinson’s Disease Mouse Model VIDEO SCREENSHOT CLICK THE BELOW LINK TO SEE THE VIDEO: https://youtu.be/L 3WmkhP2Opw © 2014-2026 HERANTIS PHARMA Plc. All rights reserved. 14

13. Slide 13: HER-096 Phase 1 Program Suggested Biological Response Aligned with MoA

    HER-096 Phase 1 Program Suggested Biological Response Aligned with MoA PHASE 1A STUDY PHASE 1B STUDY Single Ascending Dose HER-096 (10 – 300 mg) Single Dose HER-096 Multiple Doses (200 or 300 mg) Safety and PK, including CSF T½ in elderly healthy CSF T½ in elderly HV Safety, PK & biomarkers in PD pa

14. Slide 14: Phase 1 Summary: Safety and Brain Penetration in Humans

    Phase 1 summary: Safety and Brain Penetration in Humans Clean safety profile Dose-dependent CSF exposure of HER-096 demonstrated in Parkinson’s patients • Favorable safety profile observed across all tested 250 dose levels, including highest planned clinical (ng/ml) exposure 200 (ng/ml) • Low incide

15. Slide 15: Summary: Clear Biomarker Responses to HER-096 Dosing in PD Patients

    Summary: Clear Biomarker Responses to HER-096 Dosing in PD Patients Multiple Data Layers Show Concordant Shifts in Biology Aligned with Mechanism of Action Cells / Sample type System Pathways affected Interpretation Source Proteostasis and Proteostasis and redox Proteostasis modulation and CSF Neuro

16. Slide 16: HER-096 dosing: Biomarker Changes Aligned with Restoration of UPR Function in PD patients

    HER-096 dosing: Biomarker Changes Aligned with Restoration of UPR Function in PD patients Parkinson’s disease: HER-096 treatment: chronically activated Unfolded Protein Response (UPR) normalized UPR operation O2- O2- PROTEOSTASIS ↓ MITOCHONDRIAL ↓ OXIDATIVE STRESS ↑ PROTEOSTASIS↑ MITOCHONDRIAL ↑ OXI

17. Slide 17: Phase 1 Provides Human Proof of Biological Activity and De-Risks Phase 2

    Phase 1 Provides Human Proof of Biological Activity and De-Risks Phase 2 HER-096 demonstrates translation from preclinical evidence to biological activity in Parkinson’s patients Human Proof of Biological activity Preclinical Phase 1b Key Value Inflection: Evidence Phase 2 Key de-risking step Precli

18. Slide 18: Sustained Biological Effects Support Twice-Weekly HER-096 Dosing

    Sustained Biological Effects Support Twice-Weekly HER-096 Dosing Translating Sustained Biological Activity into Phase 2 Design Drug Exposure Biological Response Sustained Effect Phase 2 Translation Hours Days • Plasma half-life ~2 hours Biological effects persist Sustained biological activity • 300

19. Slide 19: Phase 2 for Efficacy Signal in Early-Stage Parkinson's Disease Patients

    Phase 2 for Efficacy Signal in Early-Stage Parkinson’s Disease Patients § A proof-of-concept study aiming to show improvement in motor symptoms • Continous objective monitoring of motor symptoms using a sensitive digital motor score (DMS) • Clinical symptom assessment (MDS-UPDRS Part II & III) • Bra

20. Slide 20: HER-096: Strong Position Within PD Disease-Modifying Landscape

    HER-096: Strong Position Within PD Disease-Modifying Landscape Uniquely broad mechanism of action addressing core pathology with potential to protect and restore neuronal function § Late-stage pipeline of disease-modifying Phase 3 / Pivotal Parkinson’s therapies remains limited • Prasinezumab (Roche

21. Slide 21: Strong External Validation and Significant Funding for Phase 2

    Strong External Validation and Significant Funding for Phase 2 €8M grant secured with multiple funding routes for the remaining need External Validation Phase 2 Financing Parkinson’s UK and MJ Fox Foundation €8M secured €25-30M remaining need • Funded the HER-096 Phase 1b clinical trial in Parkinson

22. Slide 22: Funding HER-096 Through Phase 2 Value Inflection

    Funding HER-096 Through Phase 2 Value Inflection €25–30M to reach Phase 2 efficacy data and establish disease-modifying potential in early Parkinson’s disease Strong position • Phase 1 completed: clean safety and confirmed brain penetration • Phase 1 biomarker response in PD patients aligned with me

Herantis Pharma — Investor Presentation (September 2026) on 6ix